Source:http://linkedlifedata.com/resource/pubmed/id/20350611
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2010-8-10
|
| pubmed:abstractText |
Despite advances in graft-versus-host-disease (GVHD) treatment, it is estimated that overall survival (OS) at 2 years for hematopoietic cell transplantation (HCT) recipients who experience steroid-resistant GVHD is 10%. Among recent therapeutic approaches for GVHD treatment, mesenchymal stromal cells (MSCs) hold a key position. We describe a multicenter experience of 11 pediatric patients diagnosed with acute or chronic GVHD (aGVHD, cGVHD) treated for compassionate use with GMP-grade unrelated HLA-disparate donors' bone marrow-derived MSCs, expanded in platelet-lysate (PL)-containing medium. Eleven patients (aged 4-15 years) received intravenous (i.v.) MSCs for aGVHD or cGVHD, which was resistant to multiple lines of immunosuppression. The median dose was 1.2 x 10(6)/kg (range: 0.7-3.7 x 10(6)/kg). No acute side effects were observed, and no late side effects were reported at a median follow-up of 8 months (range: 4-18 months). Overall response was obtained in 71.4% of patients, with complete response in 23.8% of cases. None of our patients presented GVHD progression upon MSC administration, but 4 patients presented GVHD recurrence 2 to 5 months after infusion. Two patients developed chronic limited GVHD. This study underlines the safety of PL-expanded MSC use in children. MSC efficacy seems to be greater in aGVHD than in cGVHD, even after failure of multiple lines of immunosuppression.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
1523-6536
|
| pubmed:author |
pubmed-author:BalduzziAdrianaA,
pubmed-author:BelottiDanielaD,
pubmed-author:BiagiEttoreE,
pubmed-author:BiondiAndreaA,
pubmed-author:BonanomiSoniaS,
pubmed-author:CapelliChiaraC,
pubmed-author:ChiusoloPatriziaP,
pubmed-author:D'AmicoGiovannaG,
pubmed-author:DanderEricaE,
pubmed-author:GaipaGiuseppeG,
pubmed-author:GolayJoseJ,
pubmed-author:IntronaMartinoM,
pubmed-author:LaninoEdoardoE,
pubmed-author:LucchiniGiovannaG,
pubmed-author:MarktelSarahS,
pubmed-author:OrofinoMaria GraziaMG,
pubmed-author:PerseghinPaoloP,
pubmed-author:RambaldiAlessandroA,
pubmed-author:RovelliAttilioA,
pubmed-author:SalvadèAgneseA,
pubmed-author:VinciPaolaP
|
| pubmed:copyrightInfo |
Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
16
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1293-301
|
| pubmed:meshHeading |
pubmed-meshheading:20350611-Adolescent,
pubmed-meshheading:20350611-Blood Platelets,
pubmed-meshheading:20350611-Child,
pubmed-meshheading:20350611-Child, Preschool,
pubmed-meshheading:20350611-Female,
pubmed-meshheading:20350611-Graft vs Host Disease,
pubmed-meshheading:20350611-Humans,
pubmed-meshheading:20350611-Male,
pubmed-meshheading:20350611-Mesenchymal Stem Cell Transplantation,
pubmed-meshheading:20350611-Mesenchymal Stem Cells,
pubmed-meshheading:20350611-Salvage Therapy,
pubmed-meshheading:20350611-Stromal Cells
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population.
|
| pubmed:affiliation |
Clinica Pediatrica, Università Milano Bicocca, Ospedale San Gerardo, Via Donizetti 106, Monza, MI, Italy.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|